Tissue Regeneration, Inc.
Gregory H. Altman, Ph.D.
President and Founder
www.tissuereg.com

EXECUTIVE SUMMARY

Tissue Regeneration, Inc (TRI) is pioneering the development of human tissue replacements for damaged or diseased soft tissue. TRI’s strength lies in its ability to create novel technology to solve large unmet market needs through a strong and unique cross-disciplinary scientific-medical team approach. TRI was incorporated in November 1998 to capitalize on the worldwide $10 billion per year Anterior Cruciate Ligament (ACL) market. Greg Altman, Ph.D., TRI President and Founder, developed a proprietary silk-based device and ACL tissue engineering methodology while working in collaboration with Tufts University’s Bioengineering Center. While the ACL remains TRI’s main focus, TRI has expanded its platform technologies to address needs in both long and short-term device and tissue markets including rotator cuff tendon (RCT) reconstruction, hernia repair, urinary stress incontinence and non-loading and loading bone grafts.

TRI is currently focused on the development of (i) device and (ii) tissue based engineered ligaments with biological, structural and functional integrity at the time of implantation. TRI has developed proprietary methods, bioreactors and biomaterial scaffolds to allow an autologous ACL to be “grown on demand” from a person’s progenitor stem cells. TRI’s ligament products consist solely of human derived adult stem cells and a novel non- mammalian derived silk protein matrix grown within an advanced bioreactor system. The company is currently focused on a device-first strategy based on promising in vivo results of its novel silk matrix alone, without cells, in both rat and goat trials.

TRI’s core expertise and patent position in biomaterials, tissue engineering and bioreactor design support a broad platform technology development plan that allows TRI to address both long-term high risk/high reward markets such as the ACL as well as short term FDA 510K markets including hernia repair.